News
SGMT
6.90
-0.43%
-0.03
Sagimet Biosciences grants 34,300 inducement stock options to new hires
PUBT · 2d ago
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Definium Therapeutics (DFTX), Apogee Therapeutics (APGE)
TipRanks · 3d ago
Weekly Report: what happened at SGMT last week (0615-0619)?
Weekly Report · 3d ago
Sagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged
TipRanks · 06/18 14:35
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga · 06/18 12:02
Weekly Report: what happened at SGMT last week (0608-0612)?
Weekly Report · 06/15 10:33
Sagimet Biosciences Announces Board Changes and Director Elections
TipRanks · 06/12 21:00
Sagimet Biosciences shareholders elect Class III directors at annual meeting
PUBT · 06/12 20:07
Weekly Report: what happened at SGMT last week (0601-0605)?
Weekly Report · 06/08 10:28
Sagimet Biosciences Grants New Performance-Based Executive Equity Awards
TipRanks · 06/03 22:07
Sagimet Biosciences grants CEO David Happel 300,000 stock options, 300,000 performance-based RSUs
PUBT · 06/03 20:36
UK's MHRA Says Resmetirom (Rezdiffra) Authorized To Treat Metabolic Dysfunction-Associated Steatohepatitis In Adults
Benzinga · 06/03 15:30
UK'S MHRA: RESMETIROM (REZDIFFRA) AUTHORISED TO TREAT METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN ADULTS
Reuters · 06/03 15:28
Weekly Report: what happened at SGMT last week (0525-0529)?
Weekly Report · 06/01 10:33
Sagimet Biosciences Presents Two Posters At EASL 2026; Denifanstat/Resmetirom Phase 1 Data Selected As Best Of EASL, With Additional Preclinical Mechanism Findings Showcased
Benzinga · 05/27 11:15
Sagimet says Phase 1 trial shows denifanstat-resmetirom combo cuts LDL cholesterol in healthy adults
PUBT · 05/27 11:03
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
Barchart · 05/27 06:00
Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from H.C. Wainwright
TipRanks · 05/26 17:47
Weekly Report: what happened at SGMT last week (0518-0522)?
Weekly Report · 05/25 10:37
More
Webull provides a variety of real-time SGMT stock news. You can receive the latest news about Sagimet Biosciences Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGMT
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.